• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

Israel OKs testing of new melanoma treatment

Article

South San Francisco, Calif. - Israel’s Ministry of Health has granted approval for biopharmaceutical firm Pain Therapeutics Inc., based here, to begin human testing of a new treatment for metastatic melanoma.

South San Francisco, Calif. - Israel’s Ministry of Health has granted approval for biopharmaceutical firm Pain Therapeutics Inc., based here, to begin human testing of a new treatment for metastatic melanoma.

Internet news source MedicalNewsToday.com reports that Pain Therapeutics’ phase 1 study will evaluate the pharmacokinetics of a proprietary radio-labeled monoclonal antibody in patients diagnosed with metastatic melanoma. The company expects to initiate this first-in-human phase 1 study in a limited number of patients in the second quarter of this year at several academic medical centers in Israel.

 

Related Videos
© 2024 MJH Life Sciences

All rights reserved.